Skip to main content
iDNA Genomics Public Ltd logo

iDNA Genomics Public Ltd — Investor Relations & Filings

Ticker · IDNA ISIN · CY0109800710 LEI · 2549006HMJWPY9CIB812 CSE Human health and social work activities
Open in API
Filings indexed 80 across all filing types
Latest filing 2024-09-30 Report Publication Anno…
Country CY Cyprus
Listing CSE IDNA

About iDNA Genomics Public Ltd

https://idnagenomics.com/en/

iDNA Genomics Public Ltd is a biotechnology company specializing in genetic analysis and precision medicine. It develops and provides DNA tests focused on three main areas: pharmacogenetics, which analyzes how genes affect a person's response to drugs; preventive medicine, which screens for genetic predispositions to diseases; and wellness genomics, which informs personalized nutrition and exercise plans. The company's product portfolio includes tests for cardiovascular health and responses to central nervous system medications. Genetic analysis is performed in its certified laboratories, supported by a proprietary bioinformatics platform and an artificial intelligence database that is continuously updated with recent scientific data to ensure accuracy. iDNA Genomics also provides the myEMR online platform for individuals and healthcare professionals to register test kits and manage genetic results.

Recent filings

Filing Released Lang Actions
Report Publication Announcement 2024
Report Publication Announcement Classification · 99% confidence The document is a formal announcement from iDNA GENOMICS PUBLIC LTD, dated September 30, 2024, addressed to the Cyprus Stock Exchange. The subject explicitly states: 'Approval and Publication of the Consolidated, Unaudited, Interim Financial Statements of IDNA GENOMICS PUBLIC LTD for the first half of 2024'. The text confirms that the Board approved the interim financial statements for the period ending June 30, 2024, prepared according to IAS 34. Crucially, the document states that these Financial Statements are 'attached to this announcement' ('επισυνάπτονται στην παρούσα ανακοίνωση') and will be posted on the website. Since the document is short (1429 chars) and its primary function is to announce the publication and availability of the actual financial report (Interim Financial Statements), it fits the definition of a Report Publication Announcement (RPA) rather than the Interim Report (IR) itself.
2024-09-30 Greek (modern)
AGM Information 2024
AGM Information Classification · 99% confidence The document is dated July 2, 2024, and is titled 'ANNOUNCEMENT' regarding the 'Results of the Annual General Meeting of the shareholders of IDNA Genomics Public Ltd'. It explicitly states that the Annual General Meeting (AGM) took place and details the outcomes, specifically the review of the Annual Financial Report for the year ended December 31, 2023, and the re-election of a board member and reappointment of auditors. Since the document reports the *results* and proceedings of the AGM, it directly relates to the AGM event itself, fitting the AGM Information (AGM-R) category, which covers presentations and materials shared during the AGM.
2024-07-02 Greek (modern)
AGM Information 2024
AGM Information Classification · 98% confidence The document is a formal announcement dated June 10, 2024, from iDNA GENOMICS PUBLIC LTD, addressed to the Cyprus Stock Exchange. The subject line explicitly states: 'ΑΝΑΚΟΙΝΩΣΗ Θέμα: Ειδοποίηση και έγγραφα Ετήσιας Γενικής Συνέλευσης' (ANNOUNCEMENT Subject: Notice and documents for the Annual General Meeting). It mentions the upcoming AGM on July 2, 2024, and states that the 'Notice of AGM' and 'Proxy Document' are attached. Since this is an announcement regarding the materials for the Annual General Meeting (AGM), it aligns best with the AGM Information category (AGM-R), which covers presentations and materials shared during the AGM. Although it announces documents, the core subject is the AGM itself, making AGM-R more specific than RPA or RNS.
2024-06-10 Greek (modern)
Audit Report / Information 2023
Audit Report / Information Classification · 98% confidence The document is titled 'ΕΚΘΕΣΗ ΚΑΙ ΕΝΟΠΟΙΗΜΕΝΕΣ ΟΙΚΟΝΟΜΙΚΕΣ ΚΑΤΑΣΤΑΣΕΙΣ 31 Δεκεμβρίου 2023' (Report and Consolidated Financial Statements December 31, 2023). It contains a detailed Table of Contents listing the Management Report ('Έκθεση Διαχείρισης'), the Independent Auditor's Report ('Έκθεση ανεξάρτητου ελεγκτή'), and the Consolidated Financial Statements (Statements of Comprehensive Income, Financial Position, Changes in Equity, and Cash Flows). The text explicitly includes the full Management Report and the Auditor's Opinion on the Consolidated Financial Statements for the year ended December 31, 2023. This structure is characteristic of a comprehensive annual financial filing, which aligns with the definition of an Annual Report (10-K), although the specific jurisdiction might use a different local designation. Given the comprehensive nature, inclusion of the auditor's report, and covering a full fiscal year, the closest standard classification is 10-K. It is not merely an Earnings Release (ER) or a short announcement (RPA/RNS) as it contains the full substance of the reports. FY 2023
2024-04-26 Greek (modern)
Investor Presentation 2024
Investor Presentation Classification · 98% confidence The document text consists of numerous slides detailing a company's focus on 'Precision Medicine,' 'Genomics,' 'DNA,' 'Genetic Testing Market,' and specific product lines like 'Pharmacogenetics' and 'Personalized Nutrigenetic Analysis.' It includes company structure, industry challenges, and a process flow from 'saliva DNA to personalized Health report.' Crucially, the latter part of the text shows a highly structured table containing technical data, sample IDs, SNP information, and processing dates (e.g., 'GSGT Version,' 'Num SNPs,' 'Sample ID,' 'RsID'). This format strongly suggests a detailed presentation or a scientific/investor briefing document, rather than a formal regulatory filing like a 10-K, an Earnings Release (ER), or a simple Dividend Notice (DIV). Given the comprehensive, slide-based structure covering strategy, market, products, and scientific detail, the most appropriate classification is Investor Presentation (IP). It is not a short announcement (RPA/RNS), nor is it a formal financial report (10-K/IR).
2024-04-16 English
Notice of Dividend Amount 2024
Notice of Dividend Amount Classification · 99% confidence The document is a short announcement dated March 13, 2024, from iDNA Genomics Public Ltd, addressed to the Cyprus Stock Exchange. The subject is the 'Payment of annual interest to the registered Bondholders' of the company's bond (ISIN CY0240422119). This explicitly details the payment of interest on debt instruments. This aligns directly with the definition of an Interest Rate Update/Notice (IRAT), which covers updates on interest rate changes affecting debt, although here it is the actual payment notification related to that interest.
2024-03-13 Greek (modern)

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.